About Enterome
Enterome is a company based in Paris (France) founded in 2008. Enterome has raised $129.73 million across 7 funding rounds from investors including Takeda Pharmaceuticals, European Investment Bank and Nestlé Health Science. Enterome offers products and services including OncoMimics™ Platform, EO2463, EO4010, and EO2401. Enterome operates in a competitive market with competitors including Moderna, BeiGene, Aclaris Therapeutics, Incyte and Horizon Therapeutics, among others.
- Headquarter Paris, France
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$129.73 M (USD)
in 7 rounds
-
Latest Funding Round
$52.25 M (USD), Series E
Jun 25, 2020
-
Investors
Takeda Pharmaceuticals
& 9 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Enterome
Enterome offers a comprehensive portfolio of products and services, including OncoMimics™ Platform, EO2463, EO4010, and EO2401.
Platform that generates immune responses for cancer treatments.
Drug for treating B cell malignancies and other tumors.
Therapy targeting colorectal cancer in clinical trials.
Treatment for adrenal tumors and related cancers.
People of Enterome
Unlock access to complete
Unlock access to complete
Funding Insights of Enterome
Enterome has successfully raised a total of $129.73M across 7 strategic funding rounds. The most recent funding activity was a Series E round of $52.25 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Enterome
Enterome has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Takeda Pharmaceuticals, European Investment Bank and Nestlé Health Science.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech & Life Sciences focused stage agnostic VC firm investing in Europe, Asia & the US
|
Locked | Locked | Locked | |
|
Private equity firm focused on energy transition and sustainable investments across Europe.
|
Locked | Locked | Locked | |
|
Early-stage investments in Italian tech and life sciences are targeted.
|
Locked | Locked | Locked |
Investor details for Enterome
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Enterome
Investment portfolio details for Enterome
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Enterome
Detailed financials for Enterome
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Enterome Comparisons
Peer comparison for Enterome
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Enterome
Enterome operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Aclaris Therapeutics, Incyte and Horizon Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
Detailed competitors of Enterome
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Enterome
Complete news archive for Enterome
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Enterome
Enterome was founded in 2008.
Enterome is headquartered in Paris, France.
Enterome is a funded company, having raised a total of $129.73M across 7 funding rounds to date.
Founded in 2008 and based in Paris, France, Enterome operates in the biotechnology sector. Drugs are developed by decoding interactions between the gut microbiome and the immune system. Two platforms have been established: OncoMimics for therapeutic cancer vaccines and EndoMimics for oral bioactives targeting inflammatory and autoimmune diseases. Focus is placed on immunomodulation for therapeutic applications.
Enterome offers OncoMimics™ Platform, EO2463, EO4010, and EO2401.
Enterome has 10 investors. Key investors include Takeda Pharmaceuticals, European Investment Bank, Nestlé Health Science, Bristol-Myers Squibb, and Symbiosis.